Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Reckitt Benckiser Says It’s Among Bidders For Merck Consumer Arm

Don't Miss Out —
Follow us on:

April 28 (Bloomberg) -- Reckitt Benckiser Group Plc, the maker of Durex condoms, said it’s among bidders for Merck & Co.’s consumer unit, a deal that would add Claritin allergy medicine and Coppertone sunblock to its growing stable of over-the-counter remedies.

“We understand that we are part of a competitive process,” the Slough, England-based company said today in a statement. “There is absolutely no certainty as to the outcome or timing of this process.”

Reckitt is among bidders including Procter & Gamble Co. and Bayer AG for the business, people familiar with the matter have said. Representatives for Bayer, P&G and Merck declined to comment earlier on the matter.

Acquiring the Merck unit would make Reckitt Benckiser the third-biggest global seller of consumer-health products, up from number nine currently. Since taking over from Bart Becht in 2011, Chief Executive Officer Rakesh Kapoor has grown Reckitt Benckiser’s consumer-health division through acquisitions to offset slowing growth at its household-cleaning unit.

The health segment accounts for about 30 percent of the company’s 10 billion pounds ($16.8 billion) in revenue, up from 5 percent in 2005, and adding the Merck brands would increase that to about 37 percent. Reckitt Benckiser, which sells a drug to help people quit heroin use, would also be paying for earnings growth after putting its pharmaceuticals business under review.

The Merck unit reported $1.9 billion in sales last year, down 3 percent from 2012 after the termination of some distribution agreements in China. Merck decided to put that business and its animal-health unit under review last year in order to allocate more capital to new drugs like its immune system-based cancer medicine, CEO Ken Frazier has said.

To contact the reporter on this story: Matthew Boyle in London at

To contact the editors responsible for this story: Celeste Perri at Robert Valpuesta

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.